肾同种移植受者使用抗淋巴细胞球蛋白的既往经验及未来研究。
Past experience and future studies with antilymphocyte globulin in recipients of kidney homografts.
作者信息
Putnam C W, Bell R H, Beart R W, Anderson J T, Weil R
出版信息
Postgrad Med J. 1976;52(5 Suppl):59-63.
PMID:792847
Abstract
We remain convinced that antilymphocyte globulin (ALG) is a potent immunosuppressive agent in humans. For that reason, we have used it in essentially every case of renal transplantation since May of 1966; now, however, we are about to embark on a controlled clinical trial of ALG in kidney transplantation and await with tremendous interest the results of other such trials from other centres around the world.
摘要
我们仍然坚信抗淋巴细胞球蛋白（ALG）在人类中是一种强效免疫抑制剂。因此，自1966年5月以来，我们在几乎每一例肾移植手术中都使用了它；然而，现在我们即将开展一项关于ALG在肾移植中的对照临床试验，并怀着极大的兴趣等待世界其他中心其他此类试验的结果。
Zotero 插件